129 related articles for article (PubMed ID: 7505877)
1. Randomized study for the treatment of adult advanced Hodgkin's disease: epirubicin, vinblastine, bleomycin, and dacarbazine (EVBD) versus mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD).
Avilés A; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Med Pediatr Oncol; 1994; 22(3):168-72. PubMed ID: 7505877
[TBL] [Abstract][Full Text] [Related]
2. Results of a randomized study of early stage Hodgkin's disease using ABVD, EBVD, or MBVD.
Avilés A; Soto B; Guzmán R; García EL; Nambo MJ; Díaz-Maqueo JC
Med Pediatr Oncol; 1995 Mar; 24(3):171-5. PubMed ID: 7530801
[TBL] [Abstract][Full Text] [Related]
3. Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.
Avilés A; Neri N; Nambo JM; Huerta-Guzman J; Talavera A; Cleto S
Leuk Lymphoma; 2005 Jul; 46(7):1023-8. PubMed ID: 16019553
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced Hodgkin's disease: EBVD versus intensive brief chemotherapy.
Avilés A; Cleto S; Neri N; Huerta-Guzmán J; Talavera A; Castañeda C; González M
Leuk Lymphoma; 2003 Aug; 44(8):1361-5. PubMed ID: 12952230
[TBL] [Abstract][Full Text] [Related]
5. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
6. [The combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP) before radiotherapy in localized stages of Hodgkin's disease. Phase II trials].
Zittoun R; Eghbali H; Audebert A; Rojouan J; David B; Blanc CM; Hoerni B; Debray J
Bull Cancer; 1987; 74(2):151-7. PubMed ID: 2440504
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
9. Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine.
Einhorn LH; Williams SD; Stevens EE; Bond WH; Chenoweth L
Cancer; 1983 Apr; 51(8):1348-52. PubMed ID: 6186356
[TBL] [Abstract][Full Text] [Related]
10. Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients. The Italian Cooperative Group on AIDS and Tumors (GICAT).
Errante D; Tirelli U; Gastaldi R; Milo D; Nosari AM; Rossi G; Fiorentini G; Carbone A; Vaccher E; Monfardini S
Cancer; 1994 Jan; 73(2):437-44. PubMed ID: 7507401
[TBL] [Abstract][Full Text] [Related]
11. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.
Viviani S; Bonadonna G; Santoro A; Bonfante V; Zanini M; Devizzi L; Soncini F; Valagussa P
J Clin Oncol; 1996 May; 14(5):1421-30. PubMed ID: 8622055
[TBL] [Abstract][Full Text] [Related]
12. Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: results of a prospective clinical trial with 70 stage IIIB-IV patients.
Fermé C; Lepage E; Brice P; D'Agay MF; Fermand JP; Castaigne S; Frija J; Miot C; Marty M; Gisselbrecht C
Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):397-405. PubMed ID: 7685749
[TBL] [Abstract][Full Text] [Related]
13. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
[TBL] [Abstract][Full Text] [Related]
14. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
[TBL] [Abstract][Full Text] [Related]
15. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.
Avilés A; Arévila N; Díaz Maqueo JC; Gómez T; García R; Nambo MJ
Leuk Lymphoma; 1993 Oct; 11(3-4):275-9. PubMed ID: 8260898
[TBL] [Abstract][Full Text] [Related]
16. ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease.
Zinzani PL; Magagnoli M; Frezza G; Barbieri E; Gherlinzoni F; Galuppi A; Bendandi M; Merla E; Albertini P; Babini L; Tura S
Leuk Lymphoma; 1999 Feb; 32(5-6):553-9. PubMed ID: 10048428
[TBL] [Abstract][Full Text] [Related]
17. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group.
Takenaka T; Mikuni C; Miura A; Sasaki T; Suzuki H; Hotta T; Hirano M; Fukuhara S; Sugiyama H; Nasu K; Dohi H; Kozuru M; Tomonaga M; Tajima K; Niimi M; Fukuda H; Mukai K; Shimoyama M
Jpn J Clin Oncol; 2000 Mar; 30(3):146-52. PubMed ID: 10798542
[TBL] [Abstract][Full Text] [Related]
18. Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy.
Brusamolino E; Orlandi E; Morra E; Castelli G; Pagnucco G; Livraghi A; Astori C; Santagostino A; Lazzarino M; Bernasconi C
Ann Oncol; 1994; 5 Suppl 2():53-7. PubMed ID: 7515648
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
[TBL] [Abstract][Full Text] [Related]
20. ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group.
Cullen MH; Stuart NS; Woodroffe C; Murphy A; Fletcher J; Blackledge GR; Child JA; Grieve RJ; Jones EL
J Clin Oncol; 1994 Apr; 12(4):779-87. PubMed ID: 7512132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
